Form 4: Winmark Director Jenele C. Grassle Reports Acquisition of Common Stock and New Stock Option Grant
Insider Transaction Report
Winmark Corp. Director Jenele C. Grassle has reported an acquisition of 2,500 shares of common stock and a new grant of 280 non-employee stock options, alongside existing option holdings, as detailed in a recent SEC Form 4 filing.
Summary
- Jenele C. Grassle, a Director of Winmark Corp. (WINA), filed a Form 4 reporting changes in her beneficial ownership.
- On June 1, 2025, Ms. Grassle acquired 2,500 shares of Winmark Common Stock, held directly.
- Additionally, on June 1, 2025, Ms. Grassle was granted 280 non-employee stock options with an exercise price of $424.82 per share.
- These newly granted options become exercisable on June 1, 2026, and expire on June 1, 2035.
- The options vest at a rate of 25% per year over four years.
- Following these transactions, Ms. Grassle directly owns 2,500 shares of Common Stock.
- She also holds a total of 10,000 non-employee stock options, including the new grant and previously issued options with exercise prices ranging from $98.25 to $446.68, and expiration dates extending to December 9, 2034.
Sentiment
Score: 7
Explanation: The sentiment is positive as a director is acquiring shares and receiving new options, indicating continued alignment with the company's performance. However, it's a routine compensation disclosure rather than a significant strategic or financial announcement.
Positives
- The acquisition of 2,500 shares of common stock by a director indicates continued confidence in the company's future performance.
- The grant of new stock options aligns the director's interests with shareholder value creation, as the options' value increases with the company's stock price.
Risks
- The value of the stock options is subject to market fluctuations; if the stock price does not exceed the exercise price, the options may expire worthless.
- The vesting schedule means the options are not immediately exercisable, tying the director's compensation to future performance over several years.
Future Outlook
The future outlook for the director's equity compensation is tied to the company's stock performance, as the value of the stock options depends on the share price exceeding their respective exercise prices. The vesting schedule of 25% per year for four years indicates a long-term incentive structure.
Management Comments
- "/s/ Jenele C. Grassle" Signature of the Reporting Person, confirming the accuracy of the filing.
Industry Context
This Form 4 filing is a routine disclosure of insider stock ownership changes, common across all publicly traded companies. It reflects standard equity compensation practices for directors, aiming to align their interests with long-term shareholder value.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Disclosure Compliance | The filing of Form 4 by a director demonstrates compliance with Section 16(a) of the Securities Exchange Act of 1934, which mandates timely reporting of changes in beneficial ownership by company insiders. | 06/03/2025 | Ensures transparency in insider holdings, which is a cornerstone of good corporate governance and investor confidence. |
Related Party Transactions
- The acquisition of common stock and the grant of non-employee stock options to a director represent compensation arrangements between the company and a related party (an insider).
Stakeholder Impact
- Shareholders: The director's increased direct ownership and long-term equity incentives align her interests with those of shareholders, potentially fostering decisions that enhance shareholder value.
- Employees: While not directly impacted, such compensation structures for leadership can signal stability and long-term vision within the company.
Next Steps
- The newly granted stock options will become exercisable in annual increments of 25% over the next four years, starting June 1, 2026.
- The director may choose to exercise vested options at any time before their respective expiration dates, subject to company policy and blackout periods.
Key Dates
| Date | Description |
|---|---|
| 06/01/2017 | Date of grant for 800 non-employee stock options with an exercise price of $98.25, exercisable on this date and expiring on 06/01/2026. |
| 12/12/2017 | Date of grant for 800 non-employee stock options with an exercise price of $125.50, exercisable on this date and expiring on 12/12/2026. |
| 06/01/2018 | Date of grant for 800 non-employee stock options with an exercise price of $122.50, exercisable on this date and expiring on 06/01/2027. |
| 12/11/2018 | Date of grant for 800 non-employee stock options with an exercise price of $134.25, exercisable on this date and expiring on 12/11/2027. |
| 06/01/2019 | Date of grant for 800 non-employee stock options with an exercise price of $143.20, exercisable on this date and expiring on 06/01/2028. |
| 12/11/2019 | Date of grant for 800 non-employee stock options with an exercise price of $156.00, exercisable on this date and expiring on 12/11/2028. |
| 06/01/2020 | Date of grant for 750 non-employee stock options with an exercise price of $164.84, exercisable on this date and expiring on 06/01/2029. |
| 12/16/2020 | Date of grant for 750 non-employee stock options with an exercise price of $176.20, exercisable on this date and expiring on 12/16/2029. |
| 06/01/2021 | Date of grant for 750 non-employee stock options with an exercise price of $143.87, exercisable on this date and expiring on 06/01/2030. |
| 12/14/2021 | Date of grant for 750 non-employee stock options with an exercise price of $183.87, exercisable on this date and expiring on 12/14/2030. |
| 06/01/2022 | Date of grant for 750 non-employee stock options with an exercise price of $195.82, exercisable on this date and expiring on 06/01/2031. |
| 12/13/2022 | Date of grant for 750 non-employee stock options with an exercise price of $261.32, exercisable on this date and expiring on 12/13/2031. |
| 06/01/2023 | Date of grant for 880 non-employee stock options with an exercise price of $197.80, exercisable on this date and expiring on 06/01/2032. |
| 12/12/2023 | Date of grant for 620 non-employee stock options with an exercise price of $238.60, exercisable on this date and expiring on 12/12/2032. |
| 06/01/2024 | Date of grant for 380 non-employee stock options with an exercise price of $325.99, exercisable on this date and expiring on 06/01/2033. |
| 12/01/2024 | Date of grant for 240 non-employee stock options with an exercise price of $446.68, exercisable on this date and expiring on 12/01/2033. |
| 06/01/2025 | Date of transaction for the acquisition of 2,500 shares of Common Stock and the grant of 280 non-employee stock options with an exercise price of $424.82. |
| 06/01/2026 | Date when the 280 non-employee stock options granted on 06/01/2025 become exercisable. |
| 12/09/2025 | Date of grant for 300 non-employee stock options with an exercise price of $400.97, exercisable on this date and expiring on 12/09/2034. |
| 06/01/2034 | Expiration date for 300 non-employee stock options granted on 06/01/2025. |
| 12/09/2034 | Expiration date for 300 non-employee stock options granted on 12/09/2025. |
| 06/01/2035 | Expiration date for the 280 non-employee stock options granted on 06/01/2025. |
Keywords
Winmark Corp, WINA, SEC Form 4, Insider Transaction, Beneficial Ownership, Stock Options, Common Stock, Director Holdings, Corporate Governance, Equity Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.